Group 1 - Newmont Corporation (NEM) has seen a 14.8% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Simmons First National Corporation (SFNC) has experienced a 7.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Vertiv Holdings Co (VRT) has recorded a 7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Dorman Products, Inc. (DORM) has seen an 11.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Masco Corporation (MAS) has also experienced an 11.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Group 1 - AdaptHealth Corp. (AHCO) specializes in home medical equipment, healthcare supplies, and related in-home services [1] - The Zacks Consensus Estimate for AdaptHealth's current year earnings has been revised 13.1% downward over the last 60 days [1] - Alexander's, Inc. (ALX) is a real estate investment trust [1] - The Zacks Consensus Estimate for Alexander's current year earnings has been revised 5.5% downward over the last 60 days [1] Group 2 - Conagra Brands, Inc. (CAG) is a packaged food company [2] - The Zacks Consensus Estimate for Conagra's current year earnings has been revised 7.9% downward over the last 60 days [2]

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, September 22nd:PHINIA Inc. (PHIN) : This company that provides fuel systems, electrical systems, and aftermarket solutions for both internal combustion engine vehicles and industrial applications carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.4% over the last 60 days.PHINIA has a PEG ratio of 0.52 compared with 1.15 for the industry. The ...

Group 1: Newmont Corporation (NEM) - Newmont Corporation is a producer and explorer of gold and other metals with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 14.8% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 15.01, compared to 24.63 for the S&P 500 [1] - Newmont possesses a Value Score of B [1] Group 2: Dorman Products, Inc. (DORM) - Dorman Products, Inc. provides replacement and enhancement components for motor vehicles and also carries a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 11.5% over the last 60 days [2] - Dorman has a price-to-earnings ratio (P/E) of 17.88, compared to 24.63 for the S&P 500 [2] - The company also possesses a Value Score of B [2]

Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 22nd:Simmons First National Corporation (SFNC) : This holding company for Simmons Bank has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days.This Zacks Rank #1 company has a dividend yield of 4.2%, compared with the industry average of 2.3%.Newmont Corporation (NEM) : This producer and explorer of gold and other metals has witnessed the Zac ...

Company Overview - Mesa Labs (MLAB) shares increased by 5.7% to close at $73.14, with notable trading volume compared to typical sessions, and a 3.4% gain over the past four weeks [1] - The company is recognized for its quality control instruments and disposable products [3] Financial Performance - Mesa Labs is expected to report quarterly earnings of $2.59 per share, reflecting a year-over-year increase of 5.7%, with revenues projected at $61.3 million, up 6% from the previous year [3] - The company recently repaid $97.5 million of its 1.375% Convertible Senior Notes due August 2025, indicating a strong execution of its strategic financial plan [2] Market Sentiment - Investor optimism is driven by Mesa Labs' steady commercial success, ongoing traction with key initiatives, and a resilient operating model [2] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [4] Industry Context - Mesa Labs operates within the Zacks Medical - Instruments industry, where Waters (WAT) is another player, closing 1.8% lower at $300.87, with a 5.5% return over the past month [4] - Waters' consensus EPS estimate has also remained unchanged at $3.22, representing a year-over-year change of 9.9% [5]

Company Overview - Agnico Eagle Mines (AEM) shares increased by 4.4% to $161.19 in the last trading session, reflecting a strong performance with higher-than-average trading volume [1] - The stock has gained 13.2% over the past four weeks, driven by rising gold prices following the U.S. Federal Reserve's interest rate cut and expectations of further cuts due to labor market concerns [1] Earnings Expectations - AEM is expected to report quarterly earnings of $1.74 per share, representing a year-over-year increase of 52.6% [2] - Revenue projections stand at $2.73 billion, which is a 26.5% increase compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for AEM has been revised 1.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - Monitoring AEM's performance is advised to see if the recent price increase can lead to sustained strength [3] Industry Context - AEM is part of the Zacks Mining - Gold industry, which includes Newmont Corporation (NEM) [4] - NEM shares also saw a 4.3% increase, closing at $81.72, with an 11.7% return over the past month [4] Newmont Corporation Overview - Newmont's consensus EPS estimate for its upcoming report has increased by 1.9% to $1.27, reflecting a year-over-year change of 56.8% [5] - Newmont also holds a Zacks Rank of 3 (Hold), similar to AEM [5]

Company Overview - Aquestive Therapeutics (AQST) shares increased by 14.8% to close at $5.67, with notable trading volume compared to typical sessions, and a total gain of 26.3% over the past four weeks [1][2] Regulatory Developments - The stock price surge is attributed to positive investor expectations regarding the FDA approval filing for its key product candidate, Anaphylm, aimed at treating severe allergic reactions. The FDA waived the advisory committee meeting, indicating a lower perceived risk associated with the treatment, with a final decision expected by January 31, 2026 [2] Financial Performance Expectations - The company is projected to report a quarterly loss of $0.13 per share, unchanged from the previous year, with expected revenues of $13.36 million, reflecting a 1.3% decline from the year-ago quarter [3] - The consensus EPS estimate for the quarter has been revised 24.4% higher over the last 30 days, suggesting a potential for price appreciation [4] Industry Comparison - Aquestive Therapeutics operates within the Zacks Medical - Drugs industry. In contrast, USANA Health Sciences (USNA) closed 3.6% lower at $29.74, with a 0.7% return over the past month. USANA's consensus EPS estimate remains unchanged at $0.47, representing a 16.1% decline from the previous year [4][5]

Group 1 - The recent quarterly results from homebuilder Lennar and restaurant operator Darden Restaurants, along with five other S&P 500 members, are included in the September-quarter tally [1] - Seven additional S&P 500 members, including Costco and Accenture, are set to report results this week, contributing to early Q3 results from nearly two dozen S&P 500 members by October 14 [2] - Q3 earnings for the S&P 500 index are expected to increase by +5.1% year-over-year, with revenues up by +6%, marking the lowest earnings growth since Q3 2023 if actual results align with expectations [3] Group 2 - Since early July, Q3 earnings estimates have risen for 5 of the 16 Zacks sectors, notably in Tech, Finance, and Energy, while the remaining sectors have faced pressure [5] - The Tech sector is projected to show robust growth, with earnings expected to rise by +11.8% and revenues by +12.5%, significantly contributing to the overall S&P 500 earnings growth [9] - Despite positive trends in the Tech sector, estimates for 11 of the 16 Zacks sectors have been under pressure, particularly in Medical, Transportation, Basic Materials, and Consumer Staples [6] Group 3 - Accenture is expected to report earnings of $2.98 per share on revenues of $17.3 billion, reflecting year-over-year increases of +6.8% and +5.6% respectively, although estimates have slightly decreased recently [17] - Costco is anticipated to report earnings of $5.81 per share on revenues of $86.14 billion, with year-over-year changes of +12.8% and +8.1%, but has seen a moderately negative revisions trend [19] - Accenture's stock has declined by -32.2% year-to-date, attributed to flat IT spending trends outside of AI and competitive threats from AI disintermediation [16]

Group 1 - Pagaya Technologies Ltd. (PGY) closed at $42.30, reflecting a -3.45% change from the previous day, underperforming compared to the S&P 500's gain of 0.49% [1] - The stock has gained 47.16% over the past month, significantly outperforming the Finance sector's gain of 3.48% and the S&P 500's gain of 2.99% [1] Group 2 - The upcoming earnings release for Pagaya Technologies is projected to show earnings per share (EPS) of $0.65, a 47.73% increase year-over-year, with revenue expected to reach $339 million, up 31.79% from the prior-year quarter [2] - Full-year Zacks Consensus Estimates predict earnings of $2.65 per share and revenue of $1.31 billion, indicating year-over-year changes of +219.28% and +28.37%, respectively [3] Group 3 - Recent adjustments to analyst estimates for Pagaya Technologies indicate changing business trends, with upward revisions reflecting analysts' positive outlook on the company's profitability [4] - The Zacks Rank system, which assesses estimate changes, currently ranks Pagaya Technologies at 2 (Buy), suggesting a favorable investment outlook [6] Group 4 - Pagaya Technologies is trading at a Forward P/E ratio of 16.53, which is a premium compared to the industry average Forward P/E of 13.56 [7] - The Financial - Miscellaneous Services industry, to which Pagaya belongs, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [7]